Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pharmaxis
ClinicalTrials.gov Identifier:
NCT00669331
First received: April 28, 2008
Last updated: January 12, 2014
Last verified: January 2014
  Purpose

No gold standard therapy exists for clearing mucus from the airways of patients with bronchiectasis. While rhDNase has a proven place in the treatment of CF, it failed to improve FEV1 in a short-term non-CF bronchiectasis study and has been shown to be detrimental after 6 months therapy in non CF bronchiectasis, moreover it has no proven effect on mucociliary clearance. Hypertonic saline has been shown to have a comparable mode of action to inhaled mannitol, but has yet to be examined as a long term treatment option in bronchiectasis.

The purpose of this study is to examine the efficacy and safety of 52 weeks treatment with inhaled mannitol in subjects with non-cystic fibrosis bronchiectasis. Previous studies with inhaled mannitol have demonstrated improvement in mucociliary clearance; mucus rehydration; improvement in quality of life and respiratory symptoms in patients with bronchiectasis and pulmonary function in cystic fibrosis. The results of this current study in combination with a recently completed 3 month study seek to confirm these early findings and to extend the evidence to support its use as a mucoactive therapy in subjects with bronchiectasis.

We hypothesize that mannitol will improve the overall health and hygiene of the lung through regular and effective clearing of the mucus load. As a consequence of the reduction in mucus load and inflammatory process, the frequency of bronchiectasis related pulmonary exacerbations and the need for exacerbation related antibiotic treatment should fall. Days in hospital and community health care costs are expected to change in line with improvements in respiratory health.

Finally, we plan to demonstrate that inhaled mannitol is safe and well tolerated over a 52 week period. We will test these hypotheses using 400 mg mannitol twice daily against control.


Condition Intervention Phase
Bronchiectasis
Drug: Inhaled mannitol
Drug: matched control
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: : A Phase III Multicenter, Randomized, Parallel Group, Controlled, Double Blind Study to Investigate the Safety and Efficacy of Inhaled Mannitol Over 12 Months in the Treatment of Bronchiectasis.

Resource links provided by NLM:


Further study details as provided by Pharmaxis:

Primary Outcome Measures:
  • • To show a significant difference in the rates of graded pulmonary exacerbations, in patients with bronchiectasis treated with inhaled mannitol compared to placebo control [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To show a significant difference in Quality of Life as measured by the St. Georges Respiratory Questionnaire (SGRQ) in patients with bronchiectasis treated with inhaled mannitol compared to placebo control [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
  • • To show a significant difference in antibiotic use prescribed for treated pulmonary exacerbations in patients with bronchiectasis treated with inhaled mannitol compared to placebo control. [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
  • • To show a significant improvement in other graded exacerbation parameters (time to first exacerbation and duration of exacerbation) in patients with bronchiectasis treated with inhaled mannitol compared to placebo control [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
  • • To show a significant difference in sputum volume in patients with bronchiectasis treated with inhaled mannitol compared to placebo control [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
  • • To show a significant difference in daytime sleepiness scores in patients with bronchiectasis treated with inhaled mannitol compared to placebo control [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
  • • To show a significant difference in lung function (FEV1, FVC, FEV1/FVC, FEF25-75 values) in patients with bronchiectasis treated with inhaled mannitol compared to placebo control [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
  • • To monitor the safety profile of inhaled mannitol compared to placebo control in subjects with bronchiectasis by investigating adverse events, airway reactivity, hematology, clinical chemistry, sputum microbiology and vital signs [ Time Frame: 52 weeks ] [ Designated as safety issue: Yes ]
  • To compare health related costs of treating patients with bronchiectasis with inhaled mannitol and placebo control [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
  • To compare health status and utility scores in patients treated with inhaled mannitol compared to placebo control [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
  • To investigate health related quality of life (HRQL) and quality adjusted life years (QALYs) by treatment group using utility scores from the Health Utilities Index Questionnaire [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
  • To investigate cost effectiveness of treating patients with bronchiectasis with inhaled mannitol [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
  • • (Exploratory) To investigate number of hospitalizations due to pulmonary exacerbations in patients with bronchiectasis treated with inhaled mannitol compared to placebo control [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]

Enrollment: 485
Study Start Date: November 2009
Study Completion Date: January 2014
Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Inhaled mannitol
Drug: Inhaled mannitol
400mg BD for 52 weeks
Placebo Comparator: 2
matched control given in same regimen as inhaled mannitol
Drug: matched control
10 capsules twice a day for 52 weeks

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  1. Have given written informed consent to participate in this study in accordance with local regulations
  2. Have documented evidence of confirmed diagnosis of (non-cystic fibrosis) bronchiectasis by CT, HRCT or bronchogram
  3. Be aged 18 - 85 years inclusive, male and female
  4. Have FEV1 ≥ 40% and ≤85% predicted* and ≥1.0L (*according to NHANES III predicted tables)measured at V0A
  5. Clinician documented history of at least 2 pulmonary exacerbations, each requiring antibiotic therapy, in the last 12 months prior to Visit 0A and a total of at least 4 in the last 2 years prior to Visit 0A
  6. Have a total SGRQ score of ≥30 at Visit 0B
  7. Have a production of ≥10g of sputum at Visit 0B Have reported chronic sputum production of ≥1 tablespoon (15mL) per day on the majority of days in the 3 months prior to Visit 0A
  8. Be able to perform all the techniques necessary to measure lung function
  9. Have FEV1 ≥40% predicted* and ≥1.0L (*according to NHANES III 1999 predicted tables) measured at V0B (Baseline result prior to MTT administration)

Exclusion Criteria

  1. Be investigators, site personnel directly affiliated with this study, or their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biologically or legally adopted.
  2. Have bronchiectasis as a consequence of cystic fibrosis or focal endobronchial lesion or otherwise curable causes (e.g. foreign body aspiration)
  3. Be considered "terminally ill" or listed for transplantation
  4. Be using hypertonic saline in the 14 days prior to commencing Visit 0B or thereafter at any time during the study
  5. Have previously used inhaled mannitol (Bronchitol) for more than a day
  6. Have had a significant episode of hemoptysis (>60 mL) in the previous 6 months
  7. Have had rescue antibiotics in the 4 weeks prior to V0B (chronic background antibiotic therapy accepted)
  8. Have smoked within the last 3 months and must not smoke during their participation in the study
  9. Have had a myocardial infarction in the three months prior to Visit 0A
  10. Have had a cerebral vascular accident in the three months prior to Visit 0A
  11. Have had major ocular surgery in the three months prior to Visit 0A
  12. Have had major abdominal, chest or brain surgery in the three months prior to Visit 0A
  13. Have a known cerebral, aortic or abdominal aneurysm
  14. Have actively treated Mycobacterium tuberculosis
  15. Have actively treated or unstable nontuberculous mycobacterial infection or be under consideration for NTM treatment in the next 12 months
  16. Have unstable ABPA requiring steroid therapy (≤5mg dose oral steroids in stable ABPA accepted)
  17. Have end stage interstitial lung disease
  18. Have active malignancy including melanoma (other skin carcinomas exempted). Remissions from any malignancy ≥2 years also exempted
  19. Be breast feeding or pregnant, or plan to become pregnant while in the study
  20. Be using an unreliable form of contraception (female subjects at risk of pregnancy only)
  21. Be participating in another investigational drug study, parallel to, or within 4 weeks of Visit 0A
  22. Have a known intolerance to mannitol or β2-agonists
  23. Have uncontrolled hypertension - e.g. for adults: systolic BP > 190 and or diastolic BP > 100
  24. Subject has a condition or is in a situation which in the Investigator's opinion may put the subject at significant risk, may confound results or may interfere significantly with the patient's participation in the study
  25. Have previously been screen failed for the study (exceptions - see section 3.3.2 Eligibility Criteria - Rescreening)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00669331

  Show 83 Study Locations
Sponsors and Collaborators
Pharmaxis
Investigators
Principal Investigator: Diana Bilton, MD Brompton Hospital London UK
Principal Investigator: Greg Tino, MD University of Pennsylvania Medical Centre, Philadelphia
Principal Investigator: Alan Barker, MD Oregon Health Sciences University, Portland Oregon
  More Information

Publications:
Responsible Party: Pharmaxis
ClinicalTrials.gov Identifier: NCT00669331     History of Changes
Other Study ID Numbers: DPM-B-305
Study First Received: April 28, 2008
Last Updated: January 12, 2014
Health Authority: United States: Food and Drug Administration
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
Australia: Department of Health and Ageing Therapeutic Goods Administration
Germany: Federal Institute for Drugs and Medical Devices
United Kingdom: Medicines and Healthcare Products Regulatory Agency
New Zealand: Medsafe
Belgium: Federal Agency for Medicinal Products and Health Products
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Chile: Instituto de Salud Pública de Chile

Keywords provided by Pharmaxis:
randomized clinical trial
mannitol
mucoactive

Additional relevant MeSH terms:
Bronchiectasis
Bronchial Diseases
Respiratory Tract Diseases
Mannitol
Diuretics, Osmotic
Diuretics
Natriuretic Agents
Physiological Effects of Drugs
Pharmacologic Actions
Cardiovascular Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on September 18, 2014